
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is a promising late-stage biopharmaceutical company with a strong pipeline of potential treatments for hereditary angioedema. Their novel oral bradykinin B2 receptor antagonists have shown positive data in Phase 2 studies for both prophylaxis and treatment of HAE attacks, and the company is currently enrolling a pivotal Phase 3 study for HAE treatment and planning a Phase 3 study for HAE prevention. With promising results and a differentiated asset in the HAE space, Pharvaris has the potential for blockbuster success, making it a strong investment opportunity.
Bears say
Pharvaris is a small biopharmaceutical company that is developing a promising drug, deucrictibant, for the treatment of hereditary angioedema (HAE) attacks. However, the company may face challenges in gaining regulatory approval due to potential changes in requirements or the need for additional data. This could limit their ability to gain market traction and negatively impact their financials in the future. Hence, a negative outlook is justified for this stock.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares